Recent news on Lenalidomide

Multiple myeloma dexamethasone / lenalidomide trial closes  -  May 16, 2007
News-Medical.net,The ECOG study also showed in that preliminary analysis that low-dose dexamethasone plus lenalidomide may result in better one-year survival rates and fewer

Multiple Myeloma Clinical Trial Closes Warly  -  May 21, 2007
eMaxHealth.com,Clinical trial, that compares a standard drug therapy, dexamethasone, with a combined therapy of the same drug plus the drug lenalidomide for people newly

SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232 ...  -  May 16, 2007
PharmaLive.com (press release),The ECOG study is evaluating the use of a low dose of dexamethasone in combination with lenalidomide as compared to the higher, standard-dose of

Data Presented At The International Symposium On Myelodysplastic ...  -  May 18, 2007
Medical News Today (press release),Additionally, among patients who showed a cytogenic response to the lenalidomide treatment, 87 percent had a ten year survival estimate compared to only

Karyotype in Myelodysplastic Syndrome Does Not Influence Efficacy ...  -  May 22, 2007
DG NewsThis feature distinguishes azacitidine from lenalidomide, which is most effective in patients with a 5q deletion chromosomal abnormality.

Patients with myelodysplastic syndromes treated with Revlimid are ...  -  May 20, 2007
News-Medical.net,Breakthrough data presented at the meeting showed that Revlimid, or lenalidomide, can provide long-term survival benefit and prevent disease progression in

Diabetes drug costs could soar 70% over next three years  -  May 18, 2007
Pharma Times (subscription),Celgene Corp's Revlimid (lenalidomide) and Pfizer's Sutent (sunitinib), and Medco noted that almost 25% of all new drugs and biologics approved last

The International Myeloma Foundation Reports Positive Shift In ...  -  May 16, 2007
PharmaLive.com (press release),...patients with REVLIMID, (lenalidomide) an oral medication from Celgene. "This is an important series of steps for myeloma patients, as we now have regimens

The International Myeloma Foundation Reports Positive Shift In ...  -  May 15, 2007
PR Newswire (press release),...the use of high dose dexamethasone, a steroid commonly used when treating patients with REVLIMID, (lenalidomide) an oral medication from Celgene.

US biotech drug spending rises while Congress debates 'biogenerics ...  -  Apr 26, 2007
LabTechnologist.com,Revlimid (lenalidomide) for multiple myeloma and Pfizer's Sutent (sunitinib) and Bayer and Onyx' Nexavar (sorafenib), both used for kidney cancer.

US biotech drug spending rises while Congress debates over ...  -  26 Apr 2007
BiopharmaReporter.com,Revlimid (lenalidomide) for multiple myeloma and Pfizer's Sutent (sunitinib) and Bayer and Onyx' Nexavar (sorafenib), both used for kidney cancer.

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03 ...  -  Apr 5, 2007
Drug Newswire (press release),REVLIMID (lenalidomide) is approved by the US Food and Drug Administration for use as a treatment in combination with standard-dose dexamethasone for

Low-dose Steroid Combined with Lenalidomide Prolongs Survival ...  -  Apr 5, 2007
PressZoom (press release),Researchers found that patients in the study who received low-dose dexamethasone and lenalidomide had a one-year survival of 96 percent compared to 86

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03 ...  -  Apr 4, 2007
PR-Inside.com (Pressemitteilung),It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID(R) (lenalidomide) may lessen the

Multiple Myeloma Clinical Trial Closes Early Due To Superior ...  -  Apr 11, 2007
Medical News Today (press release),Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus

Multiple Myeloma Clinical Trial Stops Due to Tremendous Success  -  Apr 5, 2007
SeniorJournal.com,The trial compared lenalidomide plus low-dose dexamethasone with the results from lenalidomide plus high-dose dexamethasone.

Multiple Myeloma Clinical Trial Closes Early  -  Apr 5, 2007
DG NewsLenalidomide plus high-dose dexamethasone had a one-year survival rate of 86 percent. The comparative therapy using low-dose dexamethasone showed a

Myeloma Drug Works Better at Lower Dose  -  Apr 6, 2007
Atlanta Journal Constitution (subscription),Patients were receiving the lower-dose steroid alongside another cancer-fighting drug, lenalidomide, a chemical cousin of thalidomide.

Myeloma Trial Results: A Major Success  -  Apr 5, 2007
Post ChronicleScientists said the study compared combination treatment of oral medications lenalidomide and either high- or low-dose dexamethasone in 445 patients with

Study results alter treatment for deadly form of cancer  -  Apr 5, 2007
Post-Bulletin,Oral lenalidomide and high-dose dexamethasone (standard therapy). The goal was to see whether the low-dose treatment worked as well as the high-dose one

Good news for newly diagnosed multiple myeloma patients  -  Apr 4, 2007
Post-Bulletin,Oral lenalidomide and high-dose dexamethasone (standard therapy). The goal was to see whether the low-dose treatment worked as well as the high-dose one,

Myeloma Drug Works Better at Lower Dose  -  Apr 6, 2007
Therapeutics Daily (subscription) (press release),Patients were receiving the lower-dose steroid alongside another cancer-fighting drug, lenalidomide, a chemical cousin of thalidomide.

Low-dose Dexamethasone plus Revlimid® Improves Survival over High ...  -  Apr 5, 2007
Cancer Consultants (press release),According to results recently reported in a press release by Celgene, treatment with low-dose dexamethasone (Decadron®) plus Revlimid® (lenalidomide)

The Multiple Myeloma Research Consortium And Nereus ...  -  Apr 17, 2007
Medical News Today (press release),...who are resistant to Velcade, steroid therapy, Thalomid(R) (thalidomide, Celgene Corporation) and Revlimid(R) (lenalidomide, Celgene Corporation).

Nereus Pharmaceuticals to Present Data at the American Association ...  -  Apr 9, 2007
PharmaLive.com (press release),...studies indicate NPI-0052 is active against myeloma cells from patients who are resistant to bortezomib, steroid therapy, thalidomide and lenalidomide.

Celgene says Revlimid data shows improved cancer survival rate  -  Apr 4, 2007
MarketWatchRevlimid, or lenalidomide, is a derivative of thalidomide and was first approved in 2005 as a treatment for a group of blood disorders known as

The International Myeloma Foundation Says Recommendation for ...  -  Mar 30, 2007
Drug Newswire (press release),European Union's Committee for Medicinal Products for Human Use (CHMP) recommending approval of REVLIMID(R) (lenalidomide) for patients with myeloma.

Velcade®, Alkeran®, Prednisone, and Thalomid® Effecive for ...  -  Mar 28, 2007
Cancer Consultants (press release),Revlimid® (lenalidomide), and Velcade® (bortezomib). Relapsed multiple myeloma refers to cancer that has returned after initial treatment and stopped

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),...according to Schoenebaum, are Genentech's Avastin and Summit, New Jersey–based Celgene's, Revlimid (lenalidomide). By continuing to add indications,

Celgene's thalidomide-derived Revlimid gets European nod  -  27 Mar 2007
Pharma Times (subscription),The EMEA's Committee for Medicinal Products for Human Use has given a positive opinion to Revlimid (lenalidomide), in combination with dexamethasone,

Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for ...  -  Mar 23, 2007
PR Newswire (press release),It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID (lenalidomide) may lessen the potential

Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for ...  -  Mar 23, 2007
PipelineReview.com (press release),Celgene Corporation (Nasdaq: CELG) announced today that its innovative oral cancer drug REVLIMID (lenalidomide) has received a positive opinion from the

Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for ...  -  Mar 23, 2007
Earthtimes.orgSUMMIT, NJ, March 23 -- Celgene Corporation announced today that its innovative oral cancer drug REVLIMID (lenalidomide) has received a positive opinion

Questions and Answers on the Positive Opinion for Revlimid  -  Mar 23, 2007
PharmaLive.com (press release),Revlimid is a medicine containing the active substance lenalidomide. It is to be used with dexamethasone (an anti-inflammatory medicine) to treat multiple

Committee for Medicinal Products for Human Use Summary of Positive ...  -  Mar 23, 2007
PharmaLive.com (press release),The active substance of Revlimid is lenalidomide, an immunomodulating medicinal product (ATC code: L04AX04). The precise mechanisms of action of

Meeting Highlights From The Committee For Medicinal Products For ...  -  Mar 23, 2007
Medical News Today (press release),The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Revlimid (lenalidomide), from Celgene Europe, for the treatment

From the analyst's couch: Multiple myeloma therapies  -  Mar 2, 2007
Nature.com (subscription),Lenalidomide (Revlimid; Celgene) is the most advanced IMiD and was approved by the FDA in June 2006 for the treatment of patients with MM that have failed

Oral cancer drug REVLIMID receives positive opinion  -  Mar 25, 2007
Antara (press release),Neuchatel (ANTARA News/PRNewswire-AsiaNet) - Celgene International Sarl announced today that its innovative oral cancer drug REVLIMID (lenalidomide) has

The International Myeloma Foundation Says Recommendation For ...  -  Mar 24, 2007
Medical News Today (press release),European Union's Committee for Medicinal Products for Human Use (CHMP) recommending approval of REVLIMID(R) (lenalidomide) for patients with myeloma.

Velcade®, Alkeran®, Prednisone and Thalomid® Effecive for Relapsed ...  -  Mar 23, 2007
Cancer Consultants (press release),Revlimid® (lenalidomide) and Velcade. Thalomid containing regimens are now the most commonly used induction regimens for the initial treatment of newly

Velcade® Safe and Effective for Patients with Multiple Myeloma and ...  -  Mar 15, 2007
Cancer Consultants (press release),...stem cells and the development of new agents such as Thalomid® (thalidomide), Revlimid® (lenalidomide), Doxil® (liposomal doxorubicin) and Velcade.

Improving Outcomes in Lymphoma  -  Feb 5, 2007
Medscape (subscription)Objective responses were reported in 3 of 12 patients with the immunomodulatory drug lenalidomide. [5] Tipifarnib is a farnesyl transferase inhibitor,

Drug test results signal hope in leukemia fight  -  Feb 11, 2007
St. Petersburg Times,NY, presented impressive results of a clinical trial for patients with chronic lymphocytic leukemia, treated with lenalidomide (Revlimid).

ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2007 Financial ...  -  Feb 2, 2007
PharmaLive.com (press release),...response following treatment with huN901-DM1 previously had been treated with multiple chemotherapy regimens including thalidomide and lenalidomide.

Phase II Study Of Lenalidomide In Patients With Metastatic Renal ...  -  Jan 2, 2007
Medical News Today (press release),Here, the group from Cleveland Clinic examines the activity of a derivative of thalidomide, lenalidomide, which is thought to be more potent with less

Thalidomide-Like Drug Slows Kidney Cancer Growth  -  Jan 1, 2007
Cancerpage.com,NEW YORK JAN 01, 2007 (Reuters Health) - A less-toxic relative of the drug thalidomide called lenalidomide has shown some promise in a small study of

Breakthrough For Leukemia  -  Dec 21, 2006
WFtv.com,A new drug called lenalidomide is making waves in the field of CLL. The drug is a spin-off of the drug thalidomide. Thalidomide is a drug that was used in

New Hope For Patients With Drug-Resistant Form Of Cancer  -  Dec 21, 2006
WFtv.com,Lenalidomide has mild side effects and is a powerful player against leukemia that has grown resistant to other therapies. "With the first dose,

The Multiple Myeloma Research Consortium (MMRC) and Keryx ...  -  Dec 28, 2006
PR Newswire (press release),Phase I Study to Explore the Safety and Efficacy of KRX-0401 (Perifosine) in Combination with Revlimid (Lenalidomide) and Dexamethasone in Patients with

The Multiple Myeloma Research Consortium (MMRC) And Keryx ...  -  Jan 2, 2007
Medical News Today (press release),Entitled "An Open-Label Phase I Study of the Safety of Perifosine in Combination with Lenalidomide and Dexamethasone for Patients with Relapsed or

NCCN Updates Antiemesis Guidelines  -  Jan 8, 2007
PharmaLive.com (press release),Bortezomib (Velcade, Millennium), dasatinib (Sprycel, Bristol Myers-Squibb), decitabine (Dacogen, MGI Pharma), lenalidomide (Revlimid, Celgene),

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional